Heather Platt, MD

home / authors / heather-platt-md

Clinical Research Director at Merck Research Laboratories.

Articles

Capvaxive’s EU Approval and Impact on Pneumococcal Disease Prevention: A Focus on At-Risk Populations

Capvaxive’s EU Approval and Impact on Pneumococcal Disease Prevention: A Focus on At-Risk Populations

Sophia Abene;Heather Platt, MD
March 25th 2025

Heather Platt, MD, discusses Merck’s ongoing research into real-world effectiveness and cost-effectiveness and offers a preview of data to be presented at ESCMID 2025.

Read More

Merck's Capvaxive Pneumococcal Vaccine: EU Approval Progress and Global Access

Merck's Capvaxive Pneumococcal Vaccine: EU Approval Progress and Global Access

Sophia Abene;Heather Platt, MD
March 25th 2025

Following up with Heather Platt, MD, to revisit CAPVAXIVE’s progress and global accessibility as the European Commission prepares its decision.

Read More

Latest Updated Articles

Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
With the Rise of COVID-19 Vaccines, a Greater Public Mistrust of Immunizations Has Taken Hold
Published: March 25th 2025 | Updated: March 28th 2025
With the Rise of COVID-19 Vaccines, a Greater Public Mistrust of Immunizations Has Taken Hold
FDA Approves Gepotidacin (Blujepa) for Uncomplicated Urinary Tract Infections
Published: March 25th 2025 | Updated: March 28th 2025
FDA Approves Gepotidacin (Blujepa) for Uncomplicated Urinary Tract Infections
How a Prodrug Approach May Aid In Antimalarial Development
Published: March 21st 2025 | Updated: March 28th 2025
How a Prodrug Approach May Aid In Antimalarial Development
Large Hospital System Experiences Significant Increases in Candida auris
Published: March 21st 2025 | Updated: March 28th 2025
Large Hospital System Experiences Significant Increases in Candida auris
Immunocore Reports Some PWH Achieve Viral Control and Dose-Dependent Active HIV Reservoir Reduction in IMC-M113V Trial
Published: March 17th 2025 | Updated: March 28th 2025
Immunocore Reports Some PWH Achieve Viral Control and Dose-Dependent Active HIV Reservoir Reduction in IMC-M113V Trial
© 2025 MJH Life Sciences

All rights reserved.